Swissmedic has approved Jeraygo (aprocitentan) for resistant hypertension in adults, to be used alongside at least three antihypertensives, with a recommended starting dose of 12.5 mg once daily and an option to escalate to 25 mg. The decision makes Jeraygo the first endothelin receptor antagonist available for systemic hypertension and the first new mechanistic pathway introduced into hypertension management in more than three decades. The product already has differentiated positioning across markets: as Tryvio in the United States for systemic hypertension in combination therapy, and as Jeraygo in the EU, UK, and now Switzerland specifically for resistant disease.
The approval tests whether a mechanistic step-change can unlock value in a mature, generic-heavy treatment class. Resistant hypertension is where clinical need, economic burden, and unmet outcomes converge, yet the bar for uptake is high. The central strategic question is whether durable blood pressure lowering alone will be sufficient to win payer acceptance and guideline integration in the absence of event-based outcomes, particularly against low-cost generics and device-based options now moving into practice.
The addressable population is sizable and costly: roughly one in ten hypertensive patients remain uncontrolled despite multi-drug regimens, often with obesity, chronic kidney disease, or type 2 diabetes driving risk and polypharmacy. For clinicians in cardiology, nephrology, and primary care, Jeraygo introduces the endothelin pathway into a space long dominated by RAAS blockade, calcium-channel blockers, diuretics, and mineralocorticoid receptor antagonists. Safety management will be central to adoption, with edema and fluid retention the most common adverse events and contraindications applying to pregnancy and severe hepatic impairment. Early onset of effect within two weeks and once-daily dosing align with primary care workflows but will require clear patient selection and monitoring algorithms to balance benefit and tolerability.
Evidence from the multicenter PRECISION study underpins the label. Against a standardized background triple therapy, aprocitentan 12.5 mg and 25 mg delivered statistically significant reductions in unattended automated office systolic and diastolic blood pressure at four weeks versus placebo, with consistent effects across ambulatory monitoring and sustained control through withdrawal and re-challenge phases. The consistency of response across age, sex, race, kidney function, and diabetes subgroups strengthens generalizability, positioning the drug as an add-on option when standard combinations, including mineralocorticoid antagonists, fail or are poorly tolerated.
Commercial execution now becomes the differentiator. Idorsia is engaging potential partners for Switzerland and Europe, and the asset’s transfer to Idorsia Investments Sarl amid recent financing moves suggests partnership-led commercialization is likely. Market access teams will need to frame value beyond millimeters of mercury: targeting high-risk segments where reductions translate to avoided hospitalizations, building early real-world registries to demonstrate persistence and adherence, and clarifying the place in therapy relative to spironolactone and renal denervation. In Switzerland and the EU, price negotiations will hinge on subgroup evidence, safety management protocols, and practical integration into existing resistant hypertension pathways.
The launch lands in a broader resurgence of cardiovascular innovation, where device therapies like renal denervation, cardiometabolic agents with outcome data, and precision adjuncts are redefining algorithms. As specialist therapies push into primary care, payers are rewarding real-world effectiveness and operational simplicity over mechanism alone. For competitors, Jeraygo raises the bar on pharmacologic options in resistant disease; for payers, it invites head-to-head and outcomes benchmarking against generics and devices; for Medical Affairs, it demands rapid education on edema management and systematic data capture.
The next six to twelve months will reveal whether Jeraygo can secure guideline traction, reimbursement in high-risk cohorts, and partnerships with enough reach to scale. The decisive proof point may be less the magnitude of BP reduction and more whether real-world data can link that reduction to fewer events in the patients who cost the system most.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
